If you have been reading about incretin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
==== Insulin ==== In October 1920, Frederick Banting took interest in carbohydrate metabolism while preparing a talk he was to give his physiology students at Western University in London, Ontario. He encountered an article by Moses Barron which reported an autopsy of a patient whose pancreatic stone had obstructed the main pancreatic duct, but most of the islet cells had survived intact. Banting wrote a note on October 31 of that year describing his thinking: "Ligate pancreatic ducts of dog. Keep dogs alive till acini degenerate leaving Islets. Try to isolate the internal secretion of these to relieve glycosurea [sic]" On November 8, 1920, Banting met with John Macleod, a senior professor of physiology at the University of Toronto, to ask if he might mount a research project on the internal secretion of the pancreas. Banting lacked experience in physiological research and had superficial knowledge of the subject. Nonetheless, Macleod took some interest and accepted Banting's request to work in his lab. On account of what may have interested Macleod, Michael Bliss considers the following:Speculation is in order here and is permissible because we have some idea of Macleod's knowledge of the literature. Whether he and Banting were discussing grafting or extracting, what must have appealed to Macleod as "never having been tried before" was the idea of somebody experimenting with degenerated or atrophied pancreas.
== Importance in medicine == Fehling's solution was used for many years as a diagnostic test for diabetes, a disease in which blood glucose levels are dangerously elevated by a failure to produce enough insulin (type 1 diabetes) or by an inability to respond to insulin (type 2 diabetes). Measuring the amount of oxidizing agent (in this case, Fehling's solution) reduced by glucose makes it possible to determine the concentration of glucose in the blood or urine. This then enables the right amount of insulin to be injected to bring blood glucose levels back into the normal range.
The compressional wave solutions used in the electromagnetic cloaking are transferred to material fluidic solutions where fluid motion is parallel to the wavevector. The computations then show that coordinate transformations can be applied to acoustic media when restricted to normal incidence in two dimensions. Next, the electromagnetic cloaking shell is referenced as an exact equivalence for a simulated demonstration of the acoustic cloaking shell. Bulk modulus and mass density determine the spatial dimensions of the cloak, which can bend any incident wave around the center of the shell. In a simulation with perfect conditions, because it is easier to demonstrate the principles involved, there is zero scattering in any direction.
Beyond fair pay, international labour law aims to reduce working time in line with rising productivity, for a fair work week with more holidays and time for education or retirement, unbound to an employer. Under the Fair Work Act 2009 section 61(2) there are eleven "National Employment Standards", and eight concern working time (while one is on casual work, and two are on job security). Like pay can go beyond the national minimum wage, modern awards set by the Fair Work Commission, and collective agreements between unions and employers, often do have higher standards. First, under section 62 the standard maximum working week for a full-time employee is 38 hours, and an employer may not request more "unless the additional hours are reasonable", taking account of health, family, workplace needs, any overtime payments, and notice. Under section 139 awards are permitted to, and often do include overtime pay, usually 1.5 times or 2 times the basic rate of pay. In calculating the 38 hour maximum, employees' working time over 26 weeks will be averaged out. Second most important is that employees have a right to at least four weeks' paid leave, or five weeks if the employee is a shiftworker. Third, under sections 114 to 116 there are additional paid public holidays, which vary by state but generally amount to between 8 and 12 extra days, depending on where weekends fall.
=== Television === Australian actress Zoe Caldwell's performance in the 1982 Broadway adaptation of the Jeffers' script was recorded for broadcast on the PBS series Kennedy Center Tonight. Lars von Trier made a version for television in 1988, based on the script adaptation by Carl Theodor Dreyer. Theo van Gogh directed a miniseries version that aired 2005, the year following his murder. OedipusEnders, a documentary broadcast on BBC Radio 4 on 13 April 2010, discussed similarities between soap opera and Greek theatre. One interviewee revealed that the writers for the ITV police drama series The Bill had consciously and directly drawn on Medea in writing an episode for the series. Playwright Mike Bartlett was inspired to create a modern-day suburban Medea after adapting the Euripides play for a theatre production in 2012. Bartlett's 2015–2017 BBC1 miniseries Doctor Foster follows the structure of the Greek tragedy. A Korean remake of the series, The World of the Married, became the highest-rated cable drama in Korean history, with its final episode reaching a nationwide rating of 28.371%.
Sources: en.wikipedia.org
== Further reading == Bailey, Ronald (2012). Half of The Facts You Know Are Probably Wrong, a review of Samuel Arbesman's book on Reason.com Global Summit 2006: Technology Connected Futures. Connectivism: Learning and Knowledge Today by George Siemens Babbage (2012). The Half Life of Facts, The Economist. A Q&A with Samuel Arbesman. Machlup, F. (1962). Knowledge production and distribution in the United States. Princeton, NJ: Princeton University Press. Samuel Arbesman (2012). The Half-life of Facts: Why Everything We Know Has an Expiration Date. Current Hardcover. ISBN 978-1-59184-472-3. Farnam Street Media Inc. (2018). https://fs.blog/2018/03/half-life/
==== Peptide and protein ==== Peptide hormones and protein hormones consist of three (in the case of thyrotropin-releasing hormone) to more than 200 (in the case of follicle-stimulating hormone) amino acid residues and can have a molecular mass as large as 31,000 grams per mole. All hormones secreted by the pituitary gland are peptide hormones, as are leptin from adipocytes, ghrelin from the stomach, and insulin from the pancreas.
They set out to determine whether or not the 13-minute isotope was indeed an isotope of protactinium. Between 1934 and 1938, Hahn, Meitner and Strassmann found a great number of radioactive transmutation products, all of which they regarded as transuranic. At that time, the existence of actinides was not yet established, and uranium was wrongly believed to be a group 6 element similar to tungsten. It followed that the first transuranic elements would be similar to group 7 to 10 elements, i.e. rhenium and platinoids. They established the presence of multiple isotopes of at least four such elements, and (mistakenly) identified them as elements with atomic numbers 93 through 96. They were the first scientists to measure the 23-minute half-life of uranium-239 and to establish chemically that it was an isotope of uranium, but were unable to continue this work to its logical conclusion and identify the real element 93. They identified ten different half-lives, with varying degrees of certainty. To account for them, Meitner had to hypothesise a new class of reaction and the alpha decay of uranium, neither of which had ever been reported before, and for which physical evidence was lacking. Hahn and Strassmann refined their chemical procedures, while Meitner devised new experiments to shine more light on the reaction processes.
=== Youth councils === Under the terms of the Local Government Act 2002, district councils have to represent the interests of their future communities and consider the views of people affected by their decisions. To fulfill that requirement and give young people a say in the decision-making process, many councils have a youth council. In late December 2023, the Ashburton District Council scrapped their youth council, stating they could engage better with younger people online and describing the current youth council as "a youth club where they ate pizza." In early January 2024, the Gore District Council opted to restructure its youth council and ruled out dismantling it. In April 2024, the Whanganui District Council proposed scrapping its youth council by June 2024 as part of budget saving measures.
Sources: en.wikipedia.org
On release, the game suffered from performance issues even on target hardware specifications, and shipped with a software bug that hampered the artificial intelligence of the xenomorphs in the game, making the game far less challenging than promised; it was discovered in 2019 that this bug was result of a typographic error in a configuration file shipped with the game. The game's poor performance led Sega to cancel planned releases for the Wii U. A class action lawsuit filed in April 2013 by Roger Damion Perrine and John Locke alleged that Gearbox and Sega falsely advertised Aliens: Colonial Marines by showing demos at trade shows that did not accurately represent the final product. Sega and the plaintiffs reached a settlement in late 2014, wherein Sega agreed to pay $1.25 million to the class. The plaintiffs dropped Gearbox from the suit in May 2015.
Besides the involvement of 5α-reductase in androgen signaling, it is also required for the conversion of steroid hormones such as progesterone and testosterone into neurosteroids like allopregnanolone and 3α-androstanediol, respectively. 5α-Reductase inhibitors include finasteride and dutasteride. Finasteride is a selective inhibitor of 5α-reductase types 2 and 3, while dutasteride is an inhibitor of all three isoforms of 5α-reductase. Finasteride can decrease circulating DHT levels by up to 70%, whereas dutasteride can decrease circulating DHT levels by up to 99%. Conversely, 5α-reductase inhibitors do not decrease testosterone levels, and may actually increase them slightly. 5α-Reductase inhibitors are used primarily in the treatment of benign prostatic hyperplasia, a condition in which the prostate gland becomes excessively large due to stimulation by DHT and causes unpleasant urogenital symptoms. They are also used in the treatment of androgen-dependent scalp hair loss in men and women. The medications are able to prevent further scalp hair loss in men and can restore some scalp hair density. Conversely, the effectiveness of 5α-reductase inhibitors in the treatment of scalp hair loss in women is less clear. This may be because androgen levels are much lower in women, in whom they may not play as important of a role in scalp hair loss. 5α-Reductase inhibitors are also used to treat hirsutism (excessive body/facial hair growth) in women, and are very effective for this indication.
== Mechanism of action == When a tumor stimulates the growth of new vessels, it is said to have undergone an 'angiogenic switch'. The principal stimulus for this angiogenic switch appears to be oxygen deprivation, although other stimuli such as inflammation, oncogenic mutations and mechanical stress may also play a role. The angiogenic switch leads to tumor expression of pro-angiogenic factors and increased tumor vascularization. Specifically, tumor cells release various pro-angiogenic paracrine factors (including angiogenin, vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and transforming growth factor-β (TGF-β). These stimulate endothelial cell proliferation, migration and invasion resulting in new vascular structures sprouting from nearby blood vessels. Cell adhesion molecules, such as integrins, are critical to the attachment and migration of endothelial cells to the extracellular matrix.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Purity is normally given as a percentage from reversed-phase HPLC, calculated as the main peak area relative to total peak area. Research-grade material is commonly specified at 95 per cent or higher, with tighter specifications available. The number is method-dependent and should be read alongside the chromatogram.